US 11,744,885 B2
Vaccines for recurrent respiratory papillomatosis and methods of using the same
Stephanie Ramos, Santee, CA (US); Jewell Walters, Poway, CA (US); Jian Yan, Wallingford, PA (US); Anna Slager, Lansdale, PA (US); Charles Reed, Souderton, PA (US); and Kate Broderick, San Diego, CA (US)
Assigned to Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)
Filed by Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)
Filed on May 14, 2021, as Appl. No. 17/320,944.
Claims priority of provisional application 63/024,912, filed on May 14, 2020.
Prior Publication US 2021/0353736 A1, Nov. 18, 2021
Int. Cl. A61K 39/12 (2006.01); C07K 14/025 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [C07K 14/025 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55538 (2013.01)] 35 Claims
 
1. A nucleic acid molecule encoding a human papillomavirus (HPV) antigen, the HPV antigen comprising:
the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 11; or
an amino acid sequence that is at least 95% homologous to SEQ ID NO: 1 or SEQ ID NO: 11.